🤚 The Open-Palm Illumination

There is a medical test that once cost $10 million. It now costs $5. We are not being dramatic. We are not adjusting for inflation. We are not rounding. A diagnostic procedure that once required the GDP of a small municipality can now be purchased for less than a latte in any major city where lattes are, frankly, overpriced.

Peter Diamandis — XPRIZE founder, Fountain Life co-founder, and the technology world’s most persistent optimist — dropped this statistic with the calm authority of a man who has been waiting for the rest of us to catch up. The specific test in question traces its lineage to genomic sequencing, a field whose cost curve has made Moore’s Law look like a gentle suggestion.

The Human Genome Project, completed in 2003, took 13 years and cost approximately $2.7 billion to sequence a single human genome. By 2001, the per-genome cost had dropped to a still-breathtaking $95 million. Then the exponential machinery engaged.

👐 The Two-Handed Reality Check

Let us walk through the numbers, because the numbers are frankly better than fiction.

• 2003: $2.7 billion per genome (the Human Genome Project’s final bill)
• 2009: $5,000 per genome (Complete Genomics enters the chat)
• 2014: $1,000 per genome (Illumina’s HiSeqX Ten system)
• 2024: $200 per genome (Illumina’s latest platforms)
• 2026: $80–100 per genome (Ultima Genomics and Element Biosciences’ VITARI system)

That is a 27-million-fold cost reduction in just over two decades. For context, if your rent had deflated at the same rate, your monthly housing payment would be approximately one-billionth of a cent, and your landlord would owe you money for the privilege of occupying space.

But here’s what Diamandis is actually pointing at, and it’s more interesting than the numbers: when a test costs $10 million, only governments and elite research institutions can afford it. When it costs $5, consumers can own it. That shift — from institutional monopoly to individual access — is where abundance lives. Not in the technology itself, but in who gets to use it.

Element Biosciences launched VITARI in February 2026, described as the first high-throughput benchtop sequencing system capable of delivering a high-quality whole genome at $100. Benchtop. As in, it sits on a table. In a clinic. Not in a purpose-built facility the size of a small factory with a budget approved by a congressional subcommittee.

🌿 The Gentle Awakening

The implications of this cost curve extend well beyond genomics. The pattern — absurdly expensive test becomes moderately expensive test becomes cheap test becomes something your doctor orders alongside your cholesterol panel — is repeating across diagnostics.

Diamandis’s own Fountain Life offers members an annual “Upload” consisting of 150 gigabytes of imaging, genetic, and blood-related diagnostics. The goal: detect disease at Stage 0, before symptoms appear, before the expensive emergency interventions, before the oncologist has to deliver bad news that could have been good news if someone had looked earlier.

The XPRIZE Healthspan competition pushed this even further, offering $101 million in prizes for measurable age reversal — not longevity research in the abstract, but actual, demonstrable biological age reduction in real humans. The competition wasn’t rewarding people for living longer decades from now. It was rewarding measurable results today.

And the economics are almost offensively logical: it is cheaper to find cancer at Stage 0 than to treat it at Stage 4. It is cheaper to reverse biological aging than to manage the chronic diseases of a population that ages the traditional way. Prevention isn’t just better medicine. It’s better accounting.

👑 The Crown Verdict

The story of the $10 million test that now costs $5 is not ultimately a story about technology. It is a story about who gets to know what’s happening inside their own body.

For most of human history, diagnostic medicine was something that happened to you — in a hospital, administered by a specialist, interpreted by another specialist, and billed by a third specialist whose sole expertise was the billing. The patient was the least informed person in the room.

That era is ending. When a genome sequence costs less than a sandwich, when a full-body MRI can be done in a strip mall, when AI can read your bloodwork faster and more accurately than the physician who ordered it — the asymmetry collapses. The consumer becomes the first to know, not the last.

Diamandis calls this “true abundance,” and for once, the marketing language is not overstating the case. A world where a $5 test tells you what a $10 million test told a researcher twenty years ago is a world where health outcomes are determined less by wealth and more by willingness to look.

Of course, “willingness to look” is doing a lot of heavy lifting in that sentence. But that is a human problem, not a technological one. And we’ve been solving those at a considerably slower rate.

Inspired by A $10M Medical Test Now Costs $5 | MOONSHOTS by Peter Diamandis.

Your abundance is showing. Sequence wisely.